{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:01:47Z","timestamp":1783191707631,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,11]]},"DOI":"10.7759\/cureus.87754","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T05:14:56Z","timestamp":1752297296000},"source":"Crossref","is-referenced-by-count":1,"title":["A Patient With Three Types of Hematologic Disorders and Hemophagocytic Lymphohistiocytosis Triggered by SARS-CoV-2: A Case Report"],"prefix":"10.7759","author":[{"given":"Yajing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianling","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple primary tumours: challenges and approaches, a review","volume":"2","author":"Vogt A","year":"2017","unstructured":"Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017, 2:e000172. 10.1136\/esmoopen-2017-000172","journal-title":"ESMO Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00289-7","article-title":"Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Saleem K","year":"2022","unstructured":"Saleem K, Franz J, Klem ML, et al.. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol. 2022, 9:e906-18. 10.1016\/S2352-3026(22)00289-7","journal-title":"Lancet Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1811862","article-title":"Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma","volume":"61","author":"Chinen Y","year":"2020","unstructured":"Chinen Y, Tanba K, Takagi R, et al.. Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma. Leuk Lymphoma. 2020, 61:3378-86. 10.1080\/10428194.2020.1811862","journal-title":"Leuk Lymphoma"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52182","article-title":"Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy","volume":"11","author":"Waede M","year":"2024","unstructured":"Waede M, Voss LF, Kingo C, Moeller JB, Elkjaer ML, Illes Z. Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy. Ann Clin Transl Neurol. 2024, 11:2657-72. 10.1002\/acn3.52182","journal-title":"Ann Clin Transl Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf S","year":"2022","unstructured":"DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MR, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022, 55:1779-98. 10.1016\/j.immuni.2022.09.006","journal-title":"Immunity"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta P","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020, 395:1033-4. 10.1016\/S0140-6736(20)30628-0","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90766-x","article-title":"Secondary hemophagocytic lymphohistiocytosis in severe COVID-19 - a retrospective cohort study","volume":"15","author":"Oppenauer J","year":"2025","unstructured":"Oppenauer J, Clodi-Seitz T, Kornfehl A, et al.. Secondary hemophagocytic lymphohistiocytosis in severe COVID-19 - a retrospective cohort study. Sci Rep. 2025, 15:6137. 10.1038\/s41598-025-90766-x","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36140","article-title":"Hemophagocytic syndrome and COVID-19: a comprehensive review","volume":"15","author":"Fadlallah MM","year":"2023","unstructured":"Fadlallah MM, Salman SM, Fadlallah MM, Rahal H. Hemophagocytic syndrome and COVID-19: a comprehensive review. Cureus. 2023, 15:e36140. 10.7759\/cureus.36140","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04636-y","article-title":"Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic","volume":"41","author":"Soy M","year":"2021","unstructured":"Soy M, Atag\u00fcnd\u00fcz P, Atag\u00fcnd\u00fcz I, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol Int. 2021, 41:7-18. 10.1007\/s00296-020-04636-y","journal-title":"Rheumatol Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman A","year":"2020","unstructured":"Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020, 95:316-27. 10.1002\/ajh.25696","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023","volume":"21","author":"Zelenetz AD","year":"2023","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, et al.. NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023, 21:1118-31. 10.6004\/jnccn.2023.0057","journal-title":"J Natl Compr Canc Netw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101196","article-title":"Chronic myeloid leukaemia: biology and therapy","volume":"65","author":"Wang Y","year":"2024","unstructured":"Wang Y, Liang ZJ, Gale RP, et al.. Chronic myeloid leukaemia: biology and therapy. Blood Rev. 2024, 65:101196. 10.1016\/j.blre.2024.101196","journal-title":"Blood Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e P","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, et al.. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019, 133:2465-77. 10.1182\/blood.2018894618","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019030924","article-title":"Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes","volume":"3","author":"Herr MM","year":"2019","unstructured":"Herr MM, Schonfeld SJ, Dores GM, Engels EA, Tucker MA, Curtis RE, Morton LM. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes. Blood Adv. 2019, 3:1961-9. 10.1182\/bloodadvances.2019030924","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026016","article-title":"An updated understanding of follicular lymphoma transformation [Online ahead of print]","author":"Parry EM","year":"2025","unstructured":"Parry EM, Okosun J. An updated understanding of follicular lymphoma transformation [Online ahead of print]. Blood. 2025, 10.1182\/blood.2024026016","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153067","article-title":"Composite follicular lymphoma and \"early\" (in situ and mantle zone growth pattern) mantle cell neoplasia: A rare entity with peculiar cytogenetic and clinical features","volume":"216","author":"Vivian LF","year":"2020","unstructured":"Vivian LF, Magnoli F, Campiotti L, et al.. Composite follicular lymphoma and \"early\" (in situ and mantle zone growth pattern) mantle cell neoplasia: A rare entity with peculiar cytogenetic and clinical features. Pathol Res Pract. 2020, 216:153067. 10.1016\/j.prp.2020.153067","journal-title":"Pathol Res Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.678127","article-title":"B cell orchestration of anti-tumor immune responses: a matter of cell localization and communication","volume":"9","author":"Kinker GS","year":"2021","unstructured":"Kinker GS, Vitiello GA, Ferreira WA, Chaves AS, Cordeiro de Lima VC, Medina TD. B cell orchestration of anti-tumor immune responses: a matter of cell localization and communication. Front Cell Dev Biol. 2021, 9:678127. 10.3389\/fcell.2021.678127","journal-title":"Front Cell Dev Biol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006333","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis","volume":"6","author":"Teh JS","year":"2022","unstructured":"Teh JS, Coussement J, Neoh ZC, Spelman T, Lazarakis S, Slavin MA, Teh BW. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2022, 6:2014-34. 10.1182\/bloodadvances.2021006333","journal-title":"Blood Adv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00684-8","article-title":"Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review","volume":"12","author":"Piechotta V","year":"2022","unstructured":"Piechotta V, Mellinghoff SC, Hirsch C, et al.. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer J. 2022, 12:86. 10.1038\/s41408-022-00684-8","journal-title":"Blood Cancer J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","volume":"27","author":"Apostolidis SA","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, et al.. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021, 27:1990-2001. 10.1038\/s41591-021-01507-2","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i21.3394","article-title":"Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and \u03b3-immunoglobulin infusions","volume":"7","author":"Georgiadou S","year":"2019","unstructured":"Georgiadou S, Gatselis NK, Stefos A, Zachou K, Makaritsis K, Rigopoulou EI, Dalekos GN. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and \u03b3-immunoglobulin infusions. World J Clin Cases. 2019, 7:3394-406. 10.12998\/wjcc.v7.i21.3394","journal-title":"World J Clin Cases"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01682-y","article-title":"Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?","volume":"18","author":"Opoka-Winiarska V","year":"2020","unstructured":"Opoka-Winiarska V, Grywalska E, Roli\u0144ski J. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?. BMC Med. 2020, 18:214. 10.1186\/s12916-020-01682-y","journal-title":"BMC Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06094-8","article-title":"Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients","volume":"21","author":"Meng M","year":"2021","unstructured":"Meng M, Chen L, Zhang S, et al.. Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients. BMC Infect Dis. 2021, 21:398. 10.1186\/s12879-021-06094-8","journal-title":"BMC Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.07.023","article-title":"Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma","volume":"32","author":"Breccia M","year":"2008","unstructured":"Breccia M, Martelli M, Cannella L, et al.. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma. Leuk Res. 2008, 32:353-5. 10.1016\/j.leukres.2007.07.023","journal-title":"Leuk Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7335","article-title":"Beyond BCR::ABL1-the role of genomic analyses in the management of CML","volume":"22","author":"Branford S","year":"2024","unstructured":"Branford S, Fernandes A, Shahrin N, Maqsood M, Shanmuganathan N, Wadham C. Beyond BCR::ABL1-the role of genomic analyses in the management of CML. J Natl Compr Canc Netw. 2024, 22:e237335. 10.6004\/jnccn.2023.7335","journal-title":"J Natl Compr Canc Netw"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian A","year":"2022","unstructured":"Bidikian A, Kantarjian H, Jabbour E, et al.. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 2022, 12:144. 10.1038\/s41408-022-00742-1","journal-title":"Blood Cancer J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Sch\u00f6nfeld L","year":"2022","unstructured":"Sch\u00f6nfeld L, Rinke J, Hinze A, et al.. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia. 2022, 36:2242-9. 10.1038\/s41375-022-01648-4","journal-title":"Leukemia"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad S","year":"2020","unstructured":"Adnan Awad S, Kankainen M, Ojala T, et al.. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Adv. 2020, 4:546-59. 10.1182\/bloodadvances.2019000943","journal-title":"Blood Adv"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113671","article-title":"The new ELN recommendations for treating CML","volume":"9","author":"Hehlmann R","year":"2020","unstructured":"Hehlmann R. The new ELN recommendations for treating CML. J Clin Med. 2020, 9:3671. 10.3390\/jcm9113671","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/378816-a-patient-with-three-types-of-hematologic-disorders-and-hemophagocytic-lymphohistiocytosis-triggered-by-sars-cov-2-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T05:14:58Z","timestamp":1752297298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/378816-a-patient-with-three-types-of-hematologic-disorders-and-hemophagocytic-lymphohistiocytosis-triggered-by-sars-cov-2-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.87754","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}